• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在出院后 84 天的随访中,中药对 COVID-19 恢复期患者症状、证候演变和肺部炎症吸收的影响:一项前瞻性队列和巢式病例对照研究。

Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study.

机构信息

Integrated Traditional Chinese and Western Medicine Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.

Chronic Disease Management Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.

出版信息

Chin J Integr Med. 2021 Apr;27(4):245-251. doi: 10.1007/s11655-021-3328-3. Epub 2021 Feb 3.

DOI:10.1007/s11655-021-3328-3
PMID:33534076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7857094/
Abstract

OBJECTIVE

To observe the changes of symptoms, Chinese medicine (CM) syndrome, and lung inflammation absorption during convalescence in patients with coronavirus disease 2019 (COVID-19) who had not totally recovered after hospital discharge and whether CM could promote the improvement process.

METHODS

This study was designed as a prospective cohort and nested case-control study. A total of 96 eligible patients with COVID-19 in convalescence were enrolled from Beijing Youan Hospital and Beijing Huimin Hospital and followed up from the hospital discharged day. Patients were divided into the CM (64 cases) and the control groups (32 cases) based on the treatment with or without CM and followed up at 14, 28, 56, and 84 days after discharge. In the CM group, patients received the 28-day CM treatment according to two types of CM syndrome. Improvements in clinical symptoms, CM syndrome, and absorption of lung inflammation were observed.

RESULTS

All the 96 patients completed the 84-day follow-up from January 21 to March 28, 2020. By the 84th day of follow-up, respiratory symptoms were less than 5%. There was no significant difference in the improvement rates of symptoms, including fatigue, sputum, cough, dry throat, thirst, and upset, between the two groups (P>0.05). Totally 82 patients (85.42%) showed complete lung inflammation absorption at the 84-day follow-up. On day 14, the CM group had a significantly higher absorption rate than the control group (P<0.05) and the relative risk of absorption for CM vs. control group was 3.029 (95% confidence interval: 1.026-8.940). The proportions of CM syndrome types changed with time prolonging: the proportion of the pathogen residue syndrome gradually decreased, and the proportion of both qi and yin deficiency syndrome gradually increased.

CONCLUSIONS

Patients with COVID-19 in convalescence had symptoms and lung inflammation after hospital discharge and recovered with time prolonging. CM could improve lung inflammation for early recovery. The types of CM syndrome can be transformed with time prolonging. (Registration No. ChiCTR2000029430).

摘要

目的

观察新冠肺炎出院后未完全康复患者在恢复期的症状、中医证候及肺部炎症吸收变化,探讨中医能否促进其康复过程。

方法

本研究采用前瞻性队列和嵌套病例对照研究设计。共纳入 2020 年 1 月 21 日至 3 月 28 日北京佑安医院和北京回民医院出院患者 96 例,出院当天开始随访。根据是否给予中医治疗将患者分为中医组(64 例)和对照组(32 例),分别于出院后第 14、28、56、84 天随访。中医组患者根据中医证候类型给予 28 天中医治疗。观察患者临床症状、中医证候及肺部炎症吸收的改善情况。

结果

96 例患者均完成 84 天随访。截至 2020 年 3 月 28 日,患者出院后第 84 天,呼吸症状少于 5%。两组患者症状(乏力、咳痰、咳嗽、咽干、口渴、心烦)改善率比较,差异无统计学意义(P>0.05)。84 天随访时,82 例(85.42%)患者肺部炎症完全吸收。第 14 天,中医组吸收比例高于对照组,差异有统计学意义(P<0.05),中医组与对照组比较,吸收的相对危险度为 3.029(95%可信区间:1.026~8.940)。中医证候类型随时间变化而改变:病邪残留证比例逐渐减少,气阴两虚证比例逐渐增加。

结论

新冠肺炎出院后患者仍有症状及肺部炎症,随时间延长逐渐康复。中医能促进肺部炎症的早期吸收,中医证候类型随时间延长而发生转化。(注册号:ChiCTR2000029430)

相似文献

1
Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study.在出院后 84 天的随访中,中药对 COVID-19 恢复期患者症状、证候演变和肺部炎症吸收的影响:一项前瞻性队列和巢式病例对照研究。
Chin J Integr Med. 2021 Apr;27(4):245-251. doi: 10.1007/s11655-021-3328-3. Epub 2021 Feb 3.
2
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.一项针对高风险确诊严重 SARS-CoV-2 疾病患者的随机开放标签 II 期临床试验,比较 SARS-CoV-2 感染后恢复期患者输注血浆与未输注血浆的疗效(RECOVER):一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y.
3
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.新型冠状病毒病患者核酸检测由阴转阳的机制及临床转归和法匹拉韦的疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):488. doi: 10.1186/s13063-020-04430-y.
4
Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.中药麻杏石甘-苇茎汤治疗新型冠状病毒肺炎重型急性呼吸综合征患者的疗效:一项随机对照试验研究方案的结构化总结
Trials. 2020 Dec 23;21(1):1029. doi: 10.1186/s13063-020-04970-3.
5
[Study on traditional Chinese medicine common syndrome characteristic of coronavirus disease 2019 based on latent structure combined with system clustering analysis].基于潜在结构结合系统聚类分析的2019冠状病毒病中医常见证候特征研究
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):537-543. doi: 10.3760/cma.j.cn121430-20200506-00620.
6
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
7
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
8
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.随机临床试验评估 COVID-19 住院患者使用恢复期血浆的安全性和疗效(PERUCONPLASMA):一项随机对照试验研究方案的结构化总结。
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
9
[Meta-analysis of single-group rate of the distribution of traditional Chinese medicine syndromes in 2 139 patients with coronavirus disease 2019].[2139例新型冠状病毒肺炎患者中医证候分布单组率的Meta分析]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Jun;32(6):664-670. doi: 10.3760/cma.j.cn121430-202000509-00372.
10
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.

引用本文的文献

1
A single-cell RNA sequencing dataset of peripheral blood cells in long COVID patients on herbal therapy.接受草药治疗的长期新冠患者外周血细胞的单细胞RNA测序数据集。
Sci Data. 2025 Jan 30;12(1):177. doi: 10.1038/s41597-025-04510-1.
2
Clinical effects of traditional Chinese herbal medicine management in patients with COVID-19 sequelae: A hospital-based retrospective cohort study in Taiwan.中药管理对 COVID-19 后遗症患者的临床效果:台湾基于医院的回顾性队列研究。
Int J Med Sci. 2024 May 13;21(7):1280-1291. doi: 10.7150/ijms.96575. eCollection 2024.
3
Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.精准营养以重置长期新冠病毒感染中病毒诱导的人类代谢重编程和失调(HMRD)。
NPJ Sci Food. 2024 Mar 30;8(1):19. doi: 10.1038/s41538-024-00261-2.
4
Post COVID-19 burden: focus on the short-term condition.新冠疫情后的负担:关注短期状况。
Acupunct Herb Med. 2022 Sep;2(3):139-142. doi: 10.1097/HM9.0000000000000036. Epub 2022 Dec 8.
5
The use of complementary and alternative medicine for the treatment of gastrointestinal symptoms in Long COVID: a systematic review.使用补充和替代医学治疗长新冠的胃肠道症状:一项系统综述。
Ther Adv Chronic Dis. 2023 Aug 10;14:20406223231190548. doi: 10.1177/20406223231190548. eCollection 2023.
6
The use of complementary and traditional medicine for the treatment of patients with COVID-19: A systematic review.使用补充和传统医学治疗 COVID-19 患者:系统评价。
Explore (NY). 2023 Sep-Oct;19(5):646-662. doi: 10.1016/j.explore.2023.02.005. Epub 2023 Feb 21.
7
The pathological mechanism of the COVID-19 convalescence and its treatment with traditional Chinese medicine.新型冠状病毒肺炎恢复期的病理机制及其中医药治疗
Front Pharmacol. 2023 Jan 10;13:1054312. doi: 10.3389/fphar.2022.1054312. eCollection 2022.
8
A Multimodal Approach in the Treatment of Persistent Post-COVID.一种治疗新冠后持续症状的多模式方法。
Diseases. 2022 Nov 1;10(4):97. doi: 10.3390/diseases10040097.
9
Risk factors and preventive interventions for post Covid-19 condition: systematic review.新冠后疾病的风险因素和预防干预措施:系统评价。
Emerg Microbes Infect. 2022 Dec;11(1):2762-2780. doi: 10.1080/22221751.2022.2140612.
10
Complementary and Alternative Medicine for Long COVID: Scoping Review and Bibliometric Analysis.长新冠的补充和替代医学:范围综述与文献计量分析
Evid Based Complement Alternat Med. 2022 Aug 4;2022:7303393. doi: 10.1155/2022/7303393. eCollection 2022.

本文引用的文献

1
Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.探索一种治疗 COVID-19 的综合疗法:一项随机对照试验。
Chin J Integr Med. 2020 Sep;26(9):648-655. doi: 10.1007/s11655-020-3426-7. Epub 2020 Jul 16.
2
Association between Initial Chest CT or Clinical Features and Clinical Course in Patients with Coronavirus Disease 2019 Pneumonia.新型冠状病毒肺炎患者的初始胸部 CT 或临床特征与临床病程的关系。
Korean J Radiol. 2020 Jun;21(6):736-745. doi: 10.3348/kjr.2020.0171.
3
Diagnostic value and key features of computed tomography in Coronavirus Disease 2019.计算机断层扫描在 2019 年冠状病毒病中的诊断价值和关键特征。
Emerg Microbes Infect. 2020 Dec;9(1):787-793. doi: 10.1080/22221751.2020.1750307.
4
Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19.COVID-19 阳性患者的胸部 X 线表现的频率和分布。
Radiology. 2020 Aug;296(2):E72-E78. doi: 10.1148/radiol.2020201160. Epub 2020 Mar 27.
5
Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT.放射科医生在胸部 CT 鉴别 COVID-19 与非 COVID-19 病毒性肺炎中的表现。
Radiology. 2020 Aug;296(2):E46-E54. doi: 10.1148/radiol.2020200823. Epub 2020 Mar 10.
6
Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes.COVID-19 感染的临床和高分辨率 CT 特征:初始与随访变化比较。
Invest Radiol. 2020 Jun;55(6):332-339. doi: 10.1097/RLI.0000000000000674.
7
Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19).新冠肺炎(COVID-19)康复过程中胸部 CT 肺部变化的时间进程。
Radiology. 2020 Jun;295(3):715-721. doi: 10.1148/radiol.2020200370. Epub 2020 Feb 13.
8
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情,该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
[Thoracic high resolution CT findings of 100 SARS patients in convalescent period].[100例SARS康复期患者的胸部高分辨率CT表现]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Oct;25(5):512-5.